Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.8455 | -15.9224873355 | 5.3101 | 5.3101 | 4.155 | 5986 | 4.69546961 | CS |
4 | -0.6454 | -12.6301369863 | 5.11 | 5.96 | 4.155 | 6796 | 5.10283967 | CS |
12 | -5.1179 | -53.4088181581 | 9.5825 | 9.625 | 4.155 | 53923 | 7.35455429 | CS |
26 | -11.7854 | -72.5255384615 | 16.25 | 17.75 | 4.155 | 76472 | 10.22601529 | CS |
52 | -20.2854 | -81.9612121212 | 24.75 | 24.75 | 4.155 | 82355 | 12.65570472 | CS |
156 | -20.2854 | -81.9612121212 | 24.75 | 24.75 | 4.155 | 82355 | 12.65570472 | CS |
260 | -20.2854 | -81.9612121212 | 24.75 | 24.75 | 4.155 | 82355 | 12.65570472 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관